Staff turnover in EUR114,56965,80676,852224,08862,979
Staff turnover in EUR114,56965,80676,852224,08862,979
The share: stated in EUR20212022202320242025
Shares outstanding (in mn.)49.271.151.84117.932.19
Dividend per share-----
Basic earnings per share-0.45-0.46-0.140.07-0.06
P/L in EUR million under IAS/IFRS20212022202320242025
Turnover2.91.41.60.40.2
Operating income (EBIT)-16.7-22.7-11.6-5.4-3.1
Earnings before taxes-15.4-20.8-10.6-4.9-2.8
Annual net profit/ loss-15.4-20.8-10.6-4.9-6.8
Balance sheet in EUR million under IAS/IFRS20212022202320242025
Assets
Total current assets21.97.84.23.51.7
Total fixed assets0.60.50.47.14.7
Total assets22.58.34.610.76.4
Liabilities
Total short-term liabilities4.13.32.90.81.2
Total long-term liabilities1.50.10.60.20.4
Total provisions1.30.00.40.20.4
Equity capital16.94.91.19.74.8
Total liabilities22.58.34.610.76.4
Management:
Timothy Dyer
Lénaic Teyssédou
Mikhail Kalinichev
Roger Mills
Board:
Isaac Manke
Raymond Hill
Roger Mills
Jake Nunn
Vincent Lawton
Shareholding in %:
Addex Therapeutics Ltd. 32.45
Isaac Manke 0.10
Jake R. Nunn 0.10
Mikhail Kalinichev 0.14
NEA Management Co. LLC 1.97
Raymond George Hill 0.62
Roger G. Mills 0.36
Timothy Dyer 7.71
UBS Asset Management Switzerland AG 0.86
Vincent M. Lawton 1.15
Freefloat 54.54
Address: 9, Chemin des Mines, Plan-les-Ouates, 1202 Genf
T: +41-22-884-15-55
F: +41-22-884-15-56
I: http://www.addextherapeutics.com
E: [email protected]